Your browser doesn't support javascript.
loading
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.
Bekaii-Saab, Tanios; Okusaka, Takuji; Goldstein, David; Oh, Do-Youn; Ueno, Makoto; Ioka, Tatsuya; Fang, Weijia; Anderson, Eric C; Noel, Marcus S; Reni, Michele; Choi, Hye Jin; Goldberg, Jonathan S; Oh, Sang Cheul; Li, Chung-Pin; Tabernero, Josep; Li, Jian; Foos, Emma; Oh, Cindy; Van Cutsem, Eric.
Afiliação
  • Bekaii-Saab T; Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
  • Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Goldstein D; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia.
  • Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
  • Ueno M; Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Kanagawa, Japan.
  • Ioka T; Oncology Center, Yamaguchi University Hospital, Yamaguchi, Japan.
  • Fang W; Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Anderson EC; Division of Hematology/Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA.
  • Noel MS; Department of Medicine, Division of Medical Oncology, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Reni M; Department of Oncology, Pancreas Center, IRCCS Ospedale, San Raffaele Scientific Institute, Milan, Italy.
  • Choi HJ; Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Goldberg JS; Hematology/Oncology, CareMount Medical, Mount Kisco, NY, USA.
  • Oh SC; Department of Medical Oncology, Korea University College of Medicine, Seoul, Republic of Korea.
  • Li CP; Division of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Tabernero J; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Li J; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Foos E; Medical Oncology Department, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
  • Oh C; Clinical Development, Sumitomo Pharma Oncology, Inc., Cambridge, MA, USA.
  • Van Cutsem E; Biostatistics, Sumitomo Pharma Oncology, Inc., Cambridge, MA, USA.
EClinicalMedicine ; 58: 101897, 2023 Apr.
Article em En | MEDLINE | ID: mdl-36969338
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article